How Computers Screen Millions of Peptides to Find New Drugs

This review surveys computational virtual screening methods used to discover therapeutic peptides from large libraries. Structure-based virtual screening (SBVS) is highlighted as a cost-effective approach to identify peptides that can target 'undruggable' proteins — those with large, flat surfaces that small molecule drugs cannot easily bind. The review covers applications across anticancer peptides, antimicrobial/antiviral peptides, and peptides that block amyloid fiber formation, while also addressing the challenges of using peptides as drugs (stability, delivery, bioavailability).

Literature review of computational approaches to peptide library screening, with focus on structure-based virtual screening (SBVS) strategies and their applications to diverse bioactive peptide classes.

Finding therapeutic peptides traditionally required screening millions of candidates in expensive lab experiments. Computational virtual screening dramatically reduces this cost by predicting which peptides are most likely to work before any lab testing begins. As peptide therapeutics become more important, these computational methods are accelerating drug discovery across cancer, infectious disease, and neurodegeneration.

The peptide drug market is booming, but discovering new peptide therapeutics has traditionally been slow and expensive. Computational screening is changing that equation, allowing researchers to test millions of peptide candidates in silico before committing to laboratory experiments. Combined with advances in AI and machine learning, these methods are expected to dramatically accelerate the peptide drug pipeline in the coming years.

This is a methods review, not a study with original data. Computational predictions require experimental validation, and virtual screening hit rates vary widely. The review may not cover the most recent AI/machine learning approaches that are rapidly evolving in this space.